vs
Side-by-side financial comparison of Hilltop Holdings Inc. (HTH) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $177.4M, roughly 1.7× Pacira BioSciences, Inc.). Hilltop Holdings Inc. runs the higher net margin — 13.0% vs 1.6%, a 11.3% gap on every dollar of revenue. Over the past eight quarters, Hilltop Holdings Inc.'s revenue compounded faster (0.6% CAGR vs -0.2%).
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
HTH vs PCRX — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $300.5M | $177.4M |
| Net Profit | $39.0M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | — | 3.9% |
| Net Margin | 13.0% | 1.6% |
| Revenue YoY | — | 5.0% |
| Net Profit YoY | -12.4% | — |
| EPS (diluted) | $0.64 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $300.5M | $177.4M | ||
| Q4 25 | $329.9M | $196.9M | ||
| Q3 25 | $330.2M | $179.5M | ||
| Q2 25 | $303.3M | $181.1M | ||
| Q1 25 | $318.5M | $168.9M | ||
| Q4 24 | $301.1M | $187.3M | ||
| Q3 24 | $305.5M | $168.6M | ||
| Q2 24 | $297.0M | $178.0M |
| Q1 26 | $39.0M | $2.9M | ||
| Q4 25 | $41.6M | — | ||
| Q3 25 | $45.8M | $5.4M | ||
| Q2 25 | $36.1M | $-4.8M | ||
| Q1 25 | $42.1M | $4.8M | ||
| Q4 24 | $35.5M | — | ||
| Q3 24 | $29.7M | $-143.5M | ||
| Q2 24 | $20.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 16.1% | 1.2% | ||
| Q3 25 | 18.4% | 3.5% | ||
| Q2 25 | 16.3% | 4.7% | ||
| Q1 25 | 18.1% | 1.2% | ||
| Q4 24 | 14.7% | 13.2% | ||
| Q3 24 | 13.9% | -82.8% | ||
| Q2 24 | 10.0% | 15.9% |
| Q1 26 | 13.0% | 1.6% | ||
| Q4 25 | 12.6% | — | ||
| Q3 25 | 13.9% | 3.0% | ||
| Q2 25 | 11.9% | -2.7% | ||
| Q1 25 | 13.2% | 2.8% | ||
| Q4 24 | 11.8% | — | ||
| Q3 24 | 9.7% | -85.1% | ||
| Q2 24 | 6.8% | 10.6% |
| Q1 26 | $0.64 | $0.07 | ||
| Q4 25 | $0.68 | $0.05 | ||
| Q3 25 | $0.74 | $0.12 | ||
| Q2 25 | $0.57 | $-0.11 | ||
| Q1 25 | $0.65 | $0.10 | ||
| Q4 24 | $0.55 | $0.38 | ||
| Q3 24 | $0.46 | $-3.11 | ||
| Q2 24 | $0.31 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $990.8M | — |
| Stockholders' EquityBook value | $2.2B | $653.9M |
| Total Assets | $15.7B | $1.2B |
| Debt / EquityLower = less leverage | 0.46× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | $990.8M | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $2.2B | $653.9M | ||
| Q4 25 | $2.2B | $693.1M | ||
| Q3 25 | $2.2B | $727.2M | ||
| Q2 25 | $2.2B | $757.8M | ||
| Q1 25 | $2.2B | $798.5M | ||
| Q4 24 | $2.2B | $778.3M | ||
| Q3 24 | $2.2B | $749.6M | ||
| Q2 24 | $2.1B | $879.3M |
| Q1 26 | $15.7B | $1.2B | ||
| Q4 25 | $15.8B | $1.3B | ||
| Q3 25 | $15.6B | $1.3B | ||
| Q2 25 | $15.4B | $1.5B | ||
| Q1 25 | $15.8B | $1.6B | ||
| Q4 24 | $16.3B | $1.6B | ||
| Q3 24 | $15.9B | $1.5B | ||
| Q2 24 | $15.6B | $1.6B |
| Q1 26 | 0.46× | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
